What is Cytox?
Cytox Limited specialized in leveraging polygenic risk scoring to aid pharmaceutical and biotech firms in the efficient stratification of candidates for clinical trials related to late-onset Alzheimer's disease. Their service offerings encompassed assessments of amyloid status, cognitive decline, and the profiling of mTOR-associated pathways for targeted drug development. Despite its innovative focus on precision medicine and genetic risk assessment, the company was unfortunately placed into liquidation in January 2024.
How much funding has Cytox raised?
Cytox has raised a total of $11.1M across 3 funding rounds:
Series A
$5.3M
Series B
$2.5M
Unspecified
$3.3M
Series A (2013): $5.3M, investors not publicly disclosed
Series B (2014): $2.5M led by Seneca Partners Ltd., Spark Capital, Wren Capital, and Northwest Fund
Unspecified (2017): $3.3M supported by Catapult Ventures, GM&C Life Sciences Fund, Perivoli Innovations, The Rainbow Seed Fund, and The University of Oxford
Key Investors in Cytox
Catapult Ventures
Catapult Ventures is an investment firm focused on providing tailored solutions to entrepreneurs and business owners, aiming to unlock potential and support clients in realizing their goals. They position themselves as a reliable partner for fostering growth and value through strategic partnerships.
Perivoli Innovations
Perivoli Innovations is a venture investment trust that focuses on early-stage investments in medical, life science, climate science, digital, and productivity-enhancing technologies, with a commitment to donating profits to the Perivoli Foundation for social impact initiatives.
The Rainbow Seed Fund
The Rainbow Seed Fund, managed by UKI2S, is a significant pre-seed+ fund in the UK investing in early-stage businesses and spinouts tackling global challenges in sectors like defence, engineering biology, and space, with an impact-first approach.
What's next for Cytox?
While Cytox has ceased operations, the strategic investment it received in 2017, alongside earlier funding rounds, underscores the significant interest and potential perceived in its genetic risk assessment technologies for Alzheimer's disease. The company's focus on stratifying candidates for clinical trials highlights a critical need within the pharmaceutical and biotech sectors for more efficient and precise patient selection. The capital raised was intended to advance these capabilities, suggesting a strategic direction towards enhancing drug development pipelines. The eventual liquidation indicates the inherent challenges in translating complex genetic research into sustainable commercial ventures within the highly competitive and regulated healthcare landscape.
See full Cytox company page
